First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using 68Ga-IRDye800CW-BBN

Purpose: Despite the use of fluorescence-guided surgery (FGS), maximum safe resection of glioblastoma multiforme (GBM) remains a major challenge. It has restricted surgeons between preoperative diagnosis and intraoperative treatment. Currently, an integrated approach combining preoperative assessment with intraoperative guidance would be a significant step in this direction. Experimental design: We developed a novel 68Ga-IRDye800CW-BBN PET/near-infrared fluorescence (NIRF) dual-modality imaging probe targeting gastrin-releasing peptide receptor (GRPR) in GBM. The preclinical in vivo tumor imaging and FGS were first evaluated using an orthotopic U87MG glioma xenograft model. Subsequently, the first-in-human prospective cohort study (NCT 02910804) of GBM patients were conducted with preoperative PET assessment and intraoperative FGS. Results: The orthotopic tumors in mice could be precisely resected using the near-infrared intraoperative system. Translational cohort research in 14 GBM patients demonstrated an excellent correlation between preoperative positive PET uptake and intraoperative NIRF signal. The tumor fluorescence signals were significantly higher than those from adjacent brain tissue in vivo and ex vivo (p < 0.0001). Compared with pathology, the sensitivity and specificity of fluorescence using 42 loci of fluorescence-guided sampling were 93.9% (95% CI 79.8%-99.3%) and 100% (95% CI 66.4%-100%), respectively. The tracer was safe and the extent of resection was satisfactory without newly developed neurologic deficits. Progression-free survival (PFS) at 6 months was 80% and two newly diagnosed patients achieved long PFS. Conclusions: This initial study has demonstrated that the novel dual-modality imaging technique is feasible for integrated pre- and intraoperative targeted imaging via the same molecular receptor and improved intraoperative GBM visualization and maximum safe resection.

[1]  E. Hattingen,et al.  Combination of Intraoperative Magnetic Resonance Imaging and Intraoperative Fluorescence to Enhance the Resection of Contrast Enhancing Gliomas. , 2015, Neurosurgery.

[2]  Alexander Brawanski,et al.  Sodium fluorescein–guided resection under the YELLOW 560 nm surgical microscope filter in malignant brain tumor surgery—a feasibility study , 2013, Acta Neurochirurgica.

[3]  Fan Wang,et al.  68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Xiaoyuan Chen,et al.  68Ga-NOTA-Aca-BBN(7–14) PET/CT in Healthy Volunteers and Glioma Patients , 2016, The Journal of Nuclear Medicine.

[5]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[6]  M. S. Walsum,et al.  Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging , 2013, Nature Protocols.

[7]  I. Ciric,et al.  Neurosurgical Outcomes in a Modern Series of 400 Craniotomies for Treatment of Parenchymal Tumors , 1998 .

[8]  Jie Tian,et al.  Development and application of the near-infrared and white-light thoracoscope system for minimally invasive lung cancer surgery , 2017, Journal of biomedical optics.

[9]  M. Weller,et al.  Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM , 2015, Neurology.

[10]  P. Ferroli,et al.  Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO) , 2017, Clinical Cancer Research.

[11]  P. Teixidor,et al.  Safety and Efficacy of 5-Aminolevulinic Acid for High Grade Glioma in Usual Clinical Practice: A Prospective Cohort Study , 2016, PloS one.

[12]  Georg Widhalm,et al.  What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas? , 2015, Neurosurgery.

[13]  Joshua S Richman,et al.  Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer , 2015, Clinical Cancer Research.

[14]  A G Sorensen,et al.  Comparison of diameter and perimeter methods for tumor volume calculation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Sandy Cochran,et al.  Intraoperative Ultrasound-Guided Resection of Gliomas: A Meta-Analysis and Review of the Literature. , 2016, World neurosurgery.

[16]  Neurochirurgische Klinik,et al.  Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study , 2011 .

[17]  Ricardo J. Komotar,et al.  Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? , 2013, Journal of Neuro-Oncology.

[18]  J. Uhm Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[19]  E. Hattab,et al.  Use of intraoperative fluorescein sodium fluorescence to improve the accuracy of tissue diagnosis during stereotactic needle biopsy of high-grade gliomas , 2014, Acta Neurochirurgica.

[20]  Francesco Acerbi,et al.  Fluorescein-guided surgery for malignant gliomas: a review , 2014, Neurosurgical Review.

[21]  W. Stummer,et al.  The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors , 2015, Neurosurgery.

[22]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[23]  Xiaofeng Chen,et al.  Intraoperative Fluorescence-Guided Resection of High-Grade Malignant Gliomas Using 5-Aminolevulinic Acid–Induced Porphyrins: A Systematic Review and Meta-Analysis of Prospective Studies , 2013, PloS one.

[24]  D. Prayer,et al.  5‐Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement , 2010, Cancer.

[25]  G. Reifenberger,et al.  Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. , 2015, Neuro-oncology.

[26]  Dima Suki,et al.  Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Roesler,et al.  Gastrin-releasing peptide receptor content in human glioma and normal brain , 2010, Brain Research Bulletin.

[28]  J. Sarnthein,et al.  Combining 5-Aminolevulinic Acid Fluorescence and Intraoperative Magnetic Resonance Imaging in Glioblastoma Surgery: A Histology-Based Evaluation. , 2016, Neurosurgery.

[29]  Jinzuo Ye,et al.  Comparison between the indocyanine green fluorescence and blue dye methods for sentinel lymph node biopsy using novel fluorescence image-guided resection equipment in different types of hospitals. , 2016, Translational research : the journal of laboratory and clinical medicine.

[30]  I. Yang 5-Aminolevulinic Acid Is a Promising Marker for Detection of Anaplastic Foci in Diffusely Infiltrating Gliomas With Nonsignificant Contrast Enhancement , 2011 .

[31]  Volker Seifert,et al.  Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. , 2011, The Lancet. Oncology.

[32]  Jérémie F. Cohen,et al.  STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. , 2015, Radiology.

[33]  E. Rosenthal,et al.  Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer , 2017, Clinical Cancer Research.

[34]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[35]  Melissa L. Korb,et al.  IND-Directed Safety and Biodistribution Study of Intravenously Injected Cetuximab-IRDye800 in Cynomolgus Macaques , 2015, Molecular Imaging and Biology.

[36]  Christopher Nimsky,et al.  Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. , 2011, Neuro-oncology.

[37]  John Y. K. Lee,et al.  Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging. , 2017, Journal of neurosurgery.

[38]  Jinzuo Ye,et al.  Intraoperative Imaging-Guided Cancer Surgery: From Current Fluorescence Molecular Imaging Methods to Future Multi-Modality Imaging Technology , 2014, Theranostics.

[39]  Jinzuo Ye,et al.  Increased precision of orthotopic and metastatic breast cancer surgery guided by matrix metalloproteinase-activatable near-infrared fluorescence probes , 2015, Scientific Reports.

[40]  Jörg-Christian Tonn,et al.  Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. , 2011, Journal of neurosurgery.

[41]  Vasilis Ntziachristos,et al.  Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study , 2016, Clinical Cancer Research.